Actelion`s Opsumit drug missed trial endpoint: doctor

Published 9y ago

Actelion’s Opsumit drug missed a primary endpoint in a late-stage study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, a doctor involved in the trial said in a statement from the Swiss drugmaker. More »